Proteinuria and progression of renal disease: Therapeutic implications

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 2, 1997, Pages 133-140

  Gansevoort, Ronald T ^a   Navis, Gerjan J ^a   Wapstra, Frits Hein ^a   De Jong, Paul E ^a   De Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; LISINOPRIL; METOPROLOL;

DIET; DISEASE COURSE; HUMAN; HYPERTENSION; KIDNEY DISEASE; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

EID: 0030916266     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199703000-00005     Document Type: Review

References (55)

1. Brenner BM, Meyer TW, Hostetter TH: Dietary protein and the progressive nature of kidney disease. The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. New Engl J Med 1982, 307:652-659.
2. Eddy A: Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 1989, 135:719-733.
3. Mori H, Yamashita H, Nakanishi C, Koizumi K, Makino S, Kishimoto Y, Hayashi Y: Proteinuria induced by transplantable rat pituitary MtT SA5. Model for homologous protein overload proteinuria. Lab Invest 1986, 54:636-644.
4. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990, 38:384-394.
5. Navis G, de Zeeuw D: Titrating for antiproteinuric effect: the clue for renoprotection. J Human Hypertens 1996, 10:669-673.
6. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK: Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant 1995, 10:1353-1360.
7. Halimi JM, Ribstein J, Du Cailar G, Ennouchi JM, Mimran A: Albuminuria predicts renal functional outcome after intervention in atheromatous renovascular disease. J Hypertens 1995, 13:1335-1342.
8. Perna A, Remuzzi G: Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996, 27:34-41.
9. Burton C, Harris KPG: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996, 6:765-775.
10. Iseki K, Iseki C, Ikemiya Y, Fukiyama K: Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996, 49:800-805.
11. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A and the Northern Italian Cooperative Study Group: Prospective, randomized, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Lancet 1991, 337:1299-1304.
12. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A, and the Northern Italian Cooperative Study Group: Prospective, randomized, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Nephrol Dial Transplant 1996, 11:461-467. This post-hoc analysis of a large trial investigating the alleged renoprotective effect of a low protein diet tries to identify prognostic factors related to end-stage renal failure development, especially blood pressure and proteinuria, and their (inter)relation.
13. Klahr S, Levey AS, Beck GJ, Gaggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. New Engl J Med 1994, 330:877-884.
14. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL for the MDRD Study Group: Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 1995, 123:754-762. This post-hoc analysis of the MDRD-study examines the relations among proteinuria, blood pressure and decline in GFR. The large number of patients under investigation and the elegancy of the statistical analyses make this study of outstanding interest.
15. El Nahas AM, Masters-Thomas A, Brady SA, Farrington K, Wilkinson V, Hilson AJW, Varghese Z, Moorhead JFI: Selective effect of low protein diets in chronic renal diseases. Br Med J 1984, 289:1337-1341.
16. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL: Long-term beneficial effects of ACE inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992, 20:240-248.
17. Gansevoort RT, de Zeeuw D, de Jong PE: Long-term benefits of the antiproteinuric effect of ACE inhibition in non-diabetic renal disease. Am J Kidney Dis 1993, 2:202-206.
18. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994, 45(suppl 45):174-178.
19. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994, 45(suppl 45):145-149.
20. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment Diabetologia 1994, 37:511-516.
21. Kamper AL, Strandgaard S, Leyssac PP: Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Nephrol Dial Transplant 1995, 10:1182-1188.
22. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P and the AIPRI Study Group: Effect of the angiotensin converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939-945.
23. Apperloo AJ, de Zeeuw D, de Jong PE: A short-term antihypertensive treatment induced fall in glomerular filtration rate reflects long-term protection. Kidney Int (In press).
24. Remuzzi G: Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 1995, 4:339-342.
25. Schreiner GF: Renal toxicity of albumin and other lipoproteins. Curr Opin Nephrol Hypertens 1995, 4:369-373.
26. Zoja C, Morigi M, Figluzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco P, Remuzzi G: Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995, 26:934-941.
27. Harris DCH, Chen J: Monocyte chemoattractant protein-1 (MCP-1) mRNA expression in response to protein in rat proximal tubule cells in culture [Abstract]. J Am Soc Nephrol 1995, 6:1015.
28. Burton CJ, Bevington A, Harris KPG, Walls J: Growth of proximal tubular cells in the presence of albumin and proteinuric urine. Exp Nephrol 1994, 2:345-350.
29. Joles JA, van Goor H, Braam B, Willekes-Koolschijn N, Jansen EHJM, van Tol A, Koomans HA: Proteinuria, lipoproteins and renal apolipoprotein deposits in uninephrectomized female analbuminemic rats. Kidney Int 1995, 47:442-453.
30. Joles JA, van Goor H, van der Horst MLC, van Toi A, Elema JD, Koomans HA: High lipid levels in VLDL and LDL may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats. Lab Invest 1995, 73:912-921.
31. Ghiggerri GM, Altieri P, Oleggini R, Ginevri F, Candiano G, Garberi A, Fabbretti G, Perfumo F, Gusmano R: Intact renal albumin down-regulates the extracellular matrix expression by mesangial cells and renal fibroblasts in vitro. Nephron 1994, 68:353-359.
32. Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi S, Arakawa M: Localization of apolipoprotein(a) and B-100 in various renal diseases. Kidney Int 1993, 43:430-435.
33. Pai R, Kirschenbaum MA, Kamanna VS: LDL stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int 1995, 48:1254-1262.
34. Massy ZA, Kasiske BL: Hyperlipidemia and its management in renal disease. Curr Opin Nephrol Hypertens 1996, 5:141-146.
35. Massy ZA, Ma JZ, Louis TA, Kasiske BL: Lipid lowering therapy in patients with renal disease. Kidney Int 1995, 48:188-198.
36. Manttari M, Tiula E, Alikoski T, Manninen V: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995, 26:670-675. This post-hoc analysis of the famous Helsinki Heart Study includes, to our knowledge, the first human data to suggest an association between the decline in renal function and serum lipids in a 'normal' population.
37. Cohen MP, Ziyadeh FN: Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol 1996, 7:183-190.
38. Londono I, Ghitescu L, Bendayan M: Glomerular handling of circulating glycated albumin in the normal mouse kidney. Am J Physiol 1995, 268:F913-F921.
39. Wu VY, Cohen MP: Evidence for a ligand receptor system mediating the biologic effects of glycated albumin in glomerular mesangial cells. Biochem Biophys Res Commun 1995, 207:521-528.
40. Verbeke P, Perichon M, Schaeverbeke J, Bakala H: Effect of glycation of albumin on its binding to renal brush-border membrane vesicles: influence of aging in rats. Biochim Biophys Acta 1996, 1282:93-100.
41. Cohen MP, Hud E, Wu W, Ziyadeh FN: Albumin modified by Amadori glucose adducts activates mesangial cell type IV collagen gene transcription. Mol Cell Biochem 1995, 151:61-67.
42. Sabbatini M, Sansone G, Uccello F, Giliberti A, Conte G, Andreucci VE: Early glycosilation products induce glomerular hyperfiltration. Kidney Int 1992, 42:875-881.
43. Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, Ziyadeh FN: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. J Clin Invest 1995, 95:2338-2345. This paper provides evidence that Amadori-modified proteins are deleterious to the kidney; such evidence had previously been indirect. By using a monoclonal antibody specific for Amadori-modified glycated albumin, and by showing a salutary influence of this compound on the pathogenesis of experimental diabetic nephropathy, the authors make an association between the two parameters plausible.
44. Buccala R, Vlassara H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995, 26:875-888.
45. Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD: Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 1995, 10:657-664.
46. Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E et al.: Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 1995, 10:1662-1667.
47. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation endproducts in patients with diabetic nephropathy. New Engl J Med 1991, 325:836-842.
48. Gugliucci A, Bendayan M: Renal fate of circulating AGE: evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996, 39:149-160.
49. •].
50. Lin YM, Steffes M, Donelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996, 93:3902-3907.
51. •].
52. Mogensen CE, Keane WF, Bennet PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995, 346:1080-1084.
53. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995, 10(suppl 9):39-45.
54. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995, 155:1073-1080.
55. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: The antiproteinuric effect of blood pressure lowering agents. A meta-analysis of comparative trials. Nephrol Dial Transplant 1995, 10:1963-1974. In contrast to previous meta-analyses on the antiproteinuric effect of blood pressure lowering agents, this one corrects for publication bias.